Shareholders give thumbs-up to disputed Transkaryotic takeover

A narrow majority of shareholders of Transkaryotic Therapies has approved the biotechnology firm's $1.6 billion sale to a British drug company. The takeover by Shire Pharmaceuticals had been opposed by Transkaryotics' former CEO, who quit in protest. Key investors had also argued the price that Shire is paying is too low. Dissident shareholders, including investor Carl Icahn, are expected to continue fighting the deal in court.

- read this story from the Boston Herald for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.